Biotech Values

[ghmm]

GLPG / CNCE:

I looked at CNCE and thought their earlier stage products were more interesting (from a commercial standpoint at least). With the failure of deuterated xyrem it certainly creates more doubt (in my mind at least) so I'd want to see some data.

GLPG has their own potentiator that they claim is better (I believe about 25% by one measure) which is already in humans. I believe they also had several backup compounds so even if they have a set back I don't think they would try to get CNCE's compound.

Getting to jq's point about trying to GLPG1837 in F508del homozygous does anyone know if that is a GLPG call or an ABBV call? The partnership structure is that GLPG does the Phase 1's but I wonder if that is more a strategic decision where ABBV would need to make the call.

Assuming ABBV opts in 634 I wonder what direction GLPG will go with all the cash they will have between what they have now, the IPO and the 200+possible 50 they will get from ABBV.